ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.85
-0.14%
US Tech 100
19,181.60
-0.43%
S&P 500
5,460.48
-0.41%
US Dollar vs CAD
1.36945
0.00%
Bitcoin
60,671.98
0.60%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Immunome Inc (IMNM)

  7. Immunome Inc (IMNM) News

IMNM

Immunome (IMNM)

Immunome Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IMNM
DateTimeSourceHeadlineSymbolCompany
06/27/20247:00AMBusiness WireImmunome Appoints Phil Tsai as Chief Technical OfficerNASDAQ:IMNMImmunome Inc
06/18/20248:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNMImmunome Inc
06/18/20248:05PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMNMImmunome Inc
06/18/20248:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNMImmunome Inc
06/18/20247:56PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNMImmunome Inc
06/18/20247:48PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNMImmunome Inc
06/13/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNMImmunome Inc
05/20/20247:00AMBusiness WireImmunome Announces Completion of Purchase of Assets from AtrecaNASDAQ:IMNMImmunome Inc
05/17/20244:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNMImmunome Inc
05/17/20247:00AMBusiness WireImmunome Announces Promotion of Max Rosett to Chief Financial OfficerNASDAQ:IMNMImmunome Inc
05/14/20247:48AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMNMImmunome Inc
05/14/20247:05AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMNMImmunome Inc
05/14/20247:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNMImmunome Inc
05/14/20247:00AMBusiness WireImmunome Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IMNMImmunome Inc
05/08/20247:00AMBusiness WireImmunome to Present at 2024 Bank of America Healthcare ConferenceNASDAQ:IMNMImmunome Inc
05/02/20247:00AMBusiness WireImmunome Appoints Kinney Horn as Chief Business OfficerNASDAQ:IMNMImmunome Inc
04/25/20247:26AMBusiness WireImmunome Appoints Sandra M. Swain to Board of DirectorsNASDAQ:IMNMImmunome Inc
04/05/20247:00AMBusiness WireImmunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:IMNMImmunome Inc
03/28/20243:02PMBusiness WireImmunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired AssetsNASDAQ:IMNMImmunome Inc
03/26/20247:00AMBusiness WireImmunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From AyalaNASDAQ:IMNMImmunome Inc
03/07/20247:00AMBusiness WireImmunome to Participate in the Leerink Partners Global Biopharma ConferenceNASDAQ:IMNMImmunome Inc
03/01/20247:00AMBusiness WireImmunome to Participate in the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:IMNMImmunome Inc
02/21/20248:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNMImmunome Inc
02/21/20248:07PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMNMImmunome Inc
02/20/20247:15AMBusiness WireImmunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid TumorsNASDAQ:IMNMImmunome Inc
02/16/20243:05PMBusiness WireImmunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:IMNMImmunome Inc
02/14/20243:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNMImmunome Inc
02/14/20243:09PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMNMImmunome Inc
02/13/20249:38PMBusiness WireImmunome Announces Pricing of Public Offering of Common StockNASDAQ:IMNMImmunome Inc
02/13/20243:36PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMNMImmunome Inc
 Showing the most relevant articles for your search:NASDAQ:IMNM

Your Recent History

LSE
SM39
Nationwde 42
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved